Fig. 6: Timeline and disease response in a patient with relapsed AML post-allogeneic HCT treated with TTCR-C4 and Azacitidine. | Nature Communications

Fig. 6: Timeline and disease response in a patient with relapsed AML post-allogeneic HCT treated with TTCR-C4 and Azacitidine.

From: A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence

Fig. 6: Timeline and disease response in a patient with relapsed AML post-allogeneic HCT treated with TTCR-C4 and Azacitidine.

A Timeline of patient’s treatment regimen. Dark red highlights timeframes with detectable BM AML B Percent of BM AML blasts (y-axis, log scale) by multiparametric flow cytometry (MFC) at specific timepoints (black dots, dark red shaded area). C Multimer+ cells/µl and D Percent multimer+ of CD8+ T cells in PB (black dots) and BM (red dots) collected before and after TTCR-C4 infusions. The red arrow indicates the lack of TTCR-C4 persistence before the start of Azacitidine.

Back to article page